...
首页> 外文期刊>ScientificWorldJournal >Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis
【24h】

Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

机译:增殖症或氯氮平加入奥氮翼或氯氮平的疗效:精神分裂症患者的体重控制:系统评价和荟萃分析

获取原文
           

摘要

Objectives. This study was conducted to review systematically adjunctive treatments for weight reduction in patients with schizophrenia and compare efficacies of clinical trials through meta-analysis, so as to provide effective clinical guideline regarding weight control for patients taking atypical antipsychotics.Methods. Candidate clinical trials were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Fourteen randomized clinical trials were included for systematic review and meta-analysis from 132 potential trials. The Comprehensive Meta-Analysis version 2 was used for meta-analysis.Results. Difference in means and significances from meta-analyses regarding weight control by adjunctive treatments showed that topiramate, aripiprazole, or sibutramine was more effective than metformin or reboxetine. Psychiatric evaluations did not show statistically significant changes between treatment groups and placebo groups except topiramate adjunctive treatments. Adverse effects regarding adjunctive therapies were tolerable and showed statistically no significances compared to control groups.Conclusion. Though having several reports related to exacerbation of psychiatric symptoms, topiramate and aripiprazole are more efficacious than other medications in regard to weight reduction and less burden of critical adverse effects as well as being beneficial for clinical improvement.
机译:目标。进行了本研究以审查精神分裂症患者的体重减轻,并通过荟萃分析比较临床试验的疗效,以提供有关患者的患者的重量控制,以提供有效的临床指南。方法。通过搜索受控试验,PubMed和Psycinfo的Cochrane中央登记术来确定候选临床试验。 132个潜在试验中包含十四次随机临床试验,用于系统审查和荟萃分析。综合元分析版本2用于Meta-Analysis.Results。通过辅助治疗的体重控制的荟萃分析的手段和意义的差异显示,托吡酯,阿里希哌唑或甲磺胺比二甲双胍或雷嵌丁更有效。除了Tootiramate辅助治疗之外,精神病评估没有显示治疗组和安慰剂组之间的统计学显着变化。与对照组相比,对辅助疗法的不良效果是可耐受的并且显示出统计学上没有任何意义。结论。结论。虽然有一些与精神症状的加剧相关的报告,但Topiramate和Aripiprazole比其他药物更有效,而在重量减轻和临时不良反应的负担较少以及有益于临床改善的情况下更具效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号